IGHV Mutation Status Does Not Add Prognostic Information In The Background Of Mutations In TP53 and SF3B1, and Deletions Of 17p and 11q, Which Are Independent Adverse Prognostic Parameters In CLL.
Haferlach C, Jeromin S, Weissmann S, et al.
Key Points:
Analyzed associations of IGHV mutation status with cytogenetic and molecular genetic markers; age dependency of IGHV mutation status, cytogenetic and molecular mutations; and impact on survival in 934 CLL patients.
From total of 934 patients with CLL 550/934 (58.9%) patients showed mutated and 384 (41.1%) unmutated IGHV status.
Implications:
- Several adverse markers [TP53mut, SF3B1mut, NOTCH1, del(17p), del(11q)] associated with unmutated IGHV status; accumulation of adverse markers worsens prognosis in CLL.
View the original abstract on the ASH website.
